The Effect of Oral Antiseptic Gargles on the Oral Cavity Microbiome
NCT ID: NCT03141554
Last Updated: 2017-06-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
12 participants
INTERVENTIONAL
2017-05-05
2017-05-19
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy of Mouthwash in Reducing Salivary Carriage of COVID-19
NCT04603794
Antimicrobial Activity of Two Mouthwashes
NCT02375178
Mouth Rinses for Inactivation of COVID-19
NCT04584684
Effect of Local Treatment(Carrageenan Nasal Spray and PVP-I Mouthwash) in Reducing Viral Load in Patients With COVID-19
NCT05049213
Efficacy of Mouthwashes in Reducing Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Viral Load in the Saliva
NCT04723446
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
It is envisaged that twelve healthy volunteers will complete the study. Each healthy volunteer will rinse with the test product according to a developed protocol, between established wash out periods.
The ability of the test product (1% Betadine® PVP-I based mouth wash and gargle) compared to the reference products (0.2% Chlor-Rinse™ Chlorhexidine based mouth wash (No alcohol) and Normal saline gargle) to reduce resident and transient microflora will be assessed. The mouth wash products will also be assessed for their ability to maintain and/or restore balanced microflora.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SEQUENTIAL
PREVENTION
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Treatment Sequence Group 1
Treatment Sequence Group 1 = A -\> B -\> C
Treatment A = 1% Betadine® PVP-I based mouth wash and gargle
Treatment B = 0.2% Chlor-Rinse™ Chlorhexidine based mouth wash (no alcohol)
Treatment C = Normal saline gargle (lukewarm).
1% Betadine® PVP-I based mouth wash and gargle,
1% Betadine® PVP-I based mouth wash and gargle
0.2% Chlor-Rinse™ Chlorhexidine based mouth wash
0.2% Chlor-Rinse™ Chlorhexidine based mouth wash
Normal saline gargle
Normal saline gargle
Treatment Sequence Group 2
Treatment Sequence Group 2 = B -\> C -\> A
Treatment B = 0.2% Chlor-Rinse™ Chlorhexidine based mouth wash (no alcohol)
Treatment C = Normal saline gargle (lukewarm).
Treatment A = 1% Betadine® PVP-I based mouth wash and gargle
1% Betadine® PVP-I based mouth wash and gargle,
1% Betadine® PVP-I based mouth wash and gargle
0.2% Chlor-Rinse™ Chlorhexidine based mouth wash
0.2% Chlor-Rinse™ Chlorhexidine based mouth wash
Normal saline gargle
Normal saline gargle
Treatment Sequence Group 3
Treatment Sequence Group 3 = C -\> A -\> B
Treatment C = Normal saline gargle (lukewarm).
Treatment A = 1% Betadine® PVP-I based mouth wash and gargle
Treatment B = 0.2% Chlor-Rinse™ Chlorhexidine based mouth wash (no alcohol)
1% Betadine® PVP-I based mouth wash and gargle,
1% Betadine® PVP-I based mouth wash and gargle
0.2% Chlor-Rinse™ Chlorhexidine based mouth wash
0.2% Chlor-Rinse™ Chlorhexidine based mouth wash
Normal saline gargle
Normal saline gargle
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
1% Betadine® PVP-I based mouth wash and gargle,
1% Betadine® PVP-I based mouth wash and gargle
0.2% Chlor-Rinse™ Chlorhexidine based mouth wash
0.2% Chlor-Rinse™ Chlorhexidine based mouth wash
Normal saline gargle
Normal saline gargle
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Not pregnant nor trying to conceive during the study period,
* Non-smoker, non-tobacco user (no chewing of tobacco or similar products),
* No systemic or topical oral antibiotic or antifungal in the past 2 months (from date of consent),
* No ongoing medication (e.g., immunosuppressive medication, no systemic or inhaled glucocorticoids),
* Prepared to use a toothpaste that does not any antimicrobials (Colgate Maximum Cavity Protection) for 2 days after providing consent and during the study,
* Prepared to refrain from using mouth washes/gargles or any other oral hygiene product for 2 days after providing consent and during the study,
* Good oral health (e.g., no visible bleeding, inflammation, oral ulcer or oral lesion, no need for dental treatment),
* Must have given written informed consent.
Exclusion Criteria
* Known hyperthyroidism,
* Consumption of alcoholic beverages 24 hours before test product administration on Day 0, Day 2, and Day 4,
* Wearing dental appliances (all types of braces, removable or fixed dentures, etc.),
* Minor ailments like cough, cold, upper respiratory tract infection(s), or oral ulcer(s),
* Unwillingness or inability to comply with the requirements of the protocol,
* Participation in any other drug, biologic, device, or clinical study or treatment with any investigational drug or approved therapy for investigational use within 30 days (or 5 half-lives, whichever is longer) prior to the screening visit.
21 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Singapore Polytechnic (SP)
UNKNOWN
Mundipharma Manufacturing Pte Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
National University of Singapore Hospital
Singapore, , Singapore
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BTD16-SG-401
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.